Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Someone reading a scientific publication on CT Radiomics, sarcopenia, gastric or esophageal cancer

CT-Radiomics unveils insights into sarcopenia's impact on esophageal and gastric cancer prognosis

Analyzing 83 patients with contrast-enhanced CT scans, University Hospital Ulm researchers tracked the prevalence of sarcopenia at different time points. They used mint Lesion™ for muscle segmentation and extraction of 85 radiomic features. These features, categorized into shape, first-order, and higher-order types, provided a detailed assessment of skeletal muscles. Machine learning models, including Random Forest, accurately predicted sarcopenia at the initial diagnosis.

While sarcopenia's link to disease progression lacked statistical significance, the study highlights CT radiomics and machine learning's potential in oncological imaging for refined diagnostics and prognostics.

Read more about the study here.

Related Resources

Related Resources

AI lung nodules detection in contextflow and Lung-RADS in mint Lesion

Leverage Advanced AI-Driven Nodule Detection and Analysis for Comprehensive Patient Care

Discover the power of streamlined AI-driven lung screening with contextflow ADVANCE Chest CT integrated into mint Lesion. With automated lung nodule…

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…